

Francesco Sclafani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7300923/publications.pdf>

Version: 2024-02-01

54
papers

1,298
citations

471061

17
h-index

377514

34
g-index

54
all docs

54
docs citations

54
times ranked

2626
citing authors

#	ARTICLE	IF	CITATIONS
1	Deep Epigastric Lymph Nodes Implication in Patientsâ€™ Recurrence Pattern After Cytoreductive Surgery in Colorectal Peritoneal Metastases. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 1314-1317.	0.9	2
2	Fortnightly or fractionated weekly docetaxelâ€“cisplatinâ€“5â€“FU as firstâ€“line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study. <i>Cancer Medicine</i> , 2021, 10, 4366-4374.	1.3	0
3	Targeted agents in older patients with gastrointestinal cancers â€“ An overview. <i>Journal of Geriatric Oncology</i> , 2021, 12, 1240-1252.	0.5	0
4	Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial. <i>Clinical Colorectal Cancer</i> , 2021, 20, 326-333.	1.0	2
5	European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer. <i>Cancer Treatment Reviews</i> , 2021, 99, 102208.	3.4	4
6	Debating Pros and Cons of Total Neoadjuvant Therapy in Rectal Cancer. <i>Cancers</i> , 2021, 13, 6361.	1.7	8
7	Analysis of <i>KRAS</i> , <i>NRAS</i> , <i>BRAF</i> , <i>PIK3CA</i> and <i>TP53</i> mutations in a large prospective series of locally advanced rectal cancer patients. <i>International Journal of Cancer</i> , 2020, 146, 94-102.	2.3	34
8	Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial. <i>JCO Precision Oncology</i> , 2020, 4, 1152-1162.	1.5	6
9	Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel. <i>Acta Oncologica</i> , 2020, 59, 1438-1446.	0.8	4
10	MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 311-318.e1.	1.0	4
11	Bratislava Statement: consensus recommendations for improving pancreatic cancer care. <i>ESMO Open</i> , 2020, 5, e001051.	2.0	12
12	Infiltrative tumour growth pattern correlates with poor outcome in oesophageal cancer. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000431.	1.1	2
13	Fat density is a novel prognostic marker in patients with esophageal cancer. <i>Clinical Nutrition ESPEN</i> , 2020, 39, 124-130.	0.5	8
14	Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016. <i>JAMA Network Open</i> , 2020, 3, e2024406.	2.8	53
15	International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. <i>Journal of Clinical Oncology</i> , 2020, 38, 2510-2518.	0.8	92
16	Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study. <i>ESMO Open</i> , 2020, 5, e000638.	2.0	47
17	Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. <i>Cancer Cell</i> , 2019, 36, 35-50.e9.	7.7	179
18	Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies. <i>Journal of Clinical Epidemiology</i> , 2019, 114, 49-59.	2.4	20

#	ARTICLE	IF	CITATIONS
19	Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes. <i>Scientific Reports</i> , 2019, 9, 7665.	1.6	36
20	MEK and PD-L1 inhibition in colorectal cancer: a burning blaze turning into a flash in the pan. <i>Lancet Oncology</i> , The, 2019, 20, 752-753.	5.1	7
21	Multimodality treatment of oligometastatic anal squamous cell carcinoma: A case series and literature review. <i>Journal of Surgical Oncology</i> , 2019, 119, 489-496.	0.8	14
22	KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. <i>Scientific Reports</i> , 2018, 8, 1445.	1.6	55
23	The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs. <i>Trials</i> , 2018, 19, 505.	0.7	17
24	Duration of first-line treatment for metastatic colorectal cancer: Translating the available evidence into general recommendations for routine practice. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 131, 53-65.	2.0	12
25	Building evidence-based treatment recommendations for advanced anal cancer: the time is now. <i>Lancet Oncology</i> , The, 2018, 19, 1009-1011.	5.1	1
26	Systemic Therapies for Advanced Squamous Cell Anal Cancer. <i>Current Oncology Reports</i> , 2018, 20, 53.	1.8	17
27	Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients. <i>Oncologist</i> , 2017, 22, 402-408.	1.9	31
28	Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy. <i>Oncologist</i> , 2017, 22, 728-736.	1.9	10
29	Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer. <i>British Journal of Cancer</i> , 2017, 117, 1478-1485.	2.9	118
30	PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancer. <i>Lancet Oncology</i> , The, 2017, 18, 1141-1142.	5.1	29
31	Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial. <i>International Journal of Cancer</i> , 2017, 140, 431-439.	2.3	4
32	Timing of Therapies in the Multidisciplinary Treatment of Locally Advanced Rectal Cancer: Available Evidence and Implications for Routine Practice. <i>Seminars in Radiation Oncology</i> , 2016, 26, 176-185.	1.0	6
33	Extramural Venous Invasion (EMVI) and Tumour Regression Grading (TRG) as Potential Prognostic Factors for Risk Stratification and Treatment Decision in Rectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 130-140.	1.0	5
34	Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. <i>Carcinogenesis</i> , 2016, 37, 852-857.	1.3	15
35	Response. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv405.	3.0	1
36	International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. <i>Pancreatology</i> , 2016, 16, 14-27.	0.5	81

#	ARTICLE	IF	CITATIONS
37	The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology. <i>European Journal of Cancer</i> , 2015, 51, 2732-2739.	1.3	5
38	Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): The Royal Marsden Hospital (RMH) experience. <i>BMC Cancer</i> , 2015, 15, 15.	1.1	35
39	A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv258.	3.0	72
40	Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. <i>OncoTargets and Therapy</i> , 2014, 7, 1001.	1.0	96
41	Anti-angiogenic therapies for advanced esophago-gastric cancer. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2014, 35, 253-262.	0.1	12
42	Neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer. <i>Future Oncology</i> , 2014, 10, 2243-2257.	1.1	15
43	FCR3R11a and FC3R11a Polymorphisms and Cetuximab Benefit in the Microscopic Disease. <i>Clinical Cancer Research</i> , 2014, 20, 4511-4519.	3.2	7
44	Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unit. <i>Gastric Cancer</i> , 2014, 17, 621-629.	2.7	7
45	TP53 Mutational Status and Cetuximab Benefit in Rectal Cancer: 5-Year Results of the EXPERT-C Trial. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	46
46	Cetuximab or bevacizumab in metastatic colorectal cancer?. <i>Lancet Oncology</i> , The, 2014, 15, 1040-1041.	5.1	13
47	A Pilot Study Assessing the Incidence and Clinical Significance of Circulating Tumor Cells in Esophagogastric Cancers. <i>Clinical Colorectal Cancer</i> , 2014, 13, 94-99.	1.0	28
48	Fifteen-year experience of all patients (pts) with small bowel adenocarcinoma (SBA), treated in a specialized gastrointestinal (GI) oncology unit: Royal Marsden (RM) experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, 316-316.	0.8	0
49	The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 145, 97-103.	0.4	11
50	Non-operative management for locally advanced rectal cancer: critical review and future perspective. <i>Colorectal Cancer</i> , 2013, 2, 359-370.	0.8	0
51	HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.. <i>Journal of Clinical Oncology</i> , 2013, 31, e14616-e14616.	0.8	1
52	HER-2 in high risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.. <i>Journal of Clinical Oncology</i> , 2013, 31, 420-420.	0.8	2
53	Reporting of subgroup analyses (SGA) in phase III randomized trials in gastrointestinal (GI) cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 78-78.	0.8	0
54	Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors. <i>Tumori</i> , 2011, 97, 620-8.	0.6	12